Patent US4070089A successfully refreshed from Google Patents.
Patent US2983219A successfully refreshed from Google Patents.
Patent US5082831A successfully refreshed from Google Patents.
← Back to Patent Explorer
US5082831A Expired / Lapsed US ⏱️ 0.0 years remaining

Total body washout solution and method of use

Assignee: Cryovita Laboratories Inc
•
Filing: 1989-12-05
•
Granted: 1992-01-21
•
Expires: 2009-12-05
📄 Original PDF 🌐 Google Patents 🔄 Sync Now

Abstract

Abstract The present invention is concerned with improved aqueous asanguineous perfusates, blood substitutes for profound hypothermia, and method of using the same. The perfusates comprise: -Component Molar Conc., mM Grams/liter -Hydroxyethyl starch, 40 to 60 gms -MW = 500,000 -Glucose 5-15 0.9-2.7 -Sodium bicarbonate 5-20 0.42-1.68 -Potassium chloride 15-40 1.15-3.33 -Calcium chloride 0.5-2.04 0.074-0.294 -Magnesium chloride 0.25-2.5 0.051-0.510 -HEPES or THAM 7.2-15 1.72-3.90 -Sodium phosphate, 7.2-15 -monobasic, MW = 120.0 -Mannitol or sucrose 0-170 0-30.97. -

Inventors

  • 👤 Jerry D. Leaf
  • 👤 Michael G. Federowicz

Bibliographic Details

Application Number —
Jurisdiction US
Data Source google_patents
Last Synchronized 2026-11-01 15:37
CPC Classifications
A; A61; A61K; A61K9/00; A61K9/0012; A61K9/0019; A61K9/0026; A01; A01N; A01N1/00; A01N1/10; A01N1/12; A01N1/122; A01N1/126

Claims Analysis

Total Claims: 7
Claim 1
Independent Claim 67 words
An aqueous perfusate composition comprising: ______________________________________ Component Molar Conc., mM Grams/Liter ______________________________________ Hydroxyethyl starch, 40 to 60 gms MW = 500,000 Glucose 5-15 0.9-2.7 Sodium bicarbonate 5-20 0.42-1.68 Potassium chloride 15-40 1.15-3.33 Calcium chloride 0.5-2.04 0.074-0.294 Magnesium chloride 0.25-2.5 0.051-0.51 HEPES or THAM 7.2-15 1.72-3.90 Sodium phosphate, 7.2-15 monobasic, MW = 120.0 Mannitol or sucrose 0-170 0-30.97 ______________________________________ and an effective amount of heparin to prevent coagulation.
Claim 2
Dependent Claim 67 words
An aqueous perfusate composition comprising: ______________________________________ Component Molar Conc., mM Grams/Liter ______________________________________ Hydroxyethyl starch, 40 to 60 gms MW = 500,000 Glucose 5-15 0.9-2.7 Sodium bicarbonate 5-20 0.42-1.68 Potassium chloride 15-40 1.15-3.33 Calcium chloride 0.5-2.04 0.074-0.294 Magnesium chloride 0.25-2.5 0.051-0.51 HEPES or THAM 7.2-15 1.72-3.90 Sodium phosphate, 7.2-15 monobasic, MW = 120.0 Mannitol or sucrose 0-170 0-30.97 ______________________________________ and an effective amount of heparin to prevent coagulation.
Claim 3
Dependent Claim 13 words
A perfusate composition of claim 1 containing about 1,000 IU heparin per liter.
Claim 4
Dependent Claim 19 words
A perfusate composition of claim 1, the pH of which has been adjusted to about 8.0 to about 8.2.
Claim 5
Dependent Claim 13 words
A perfusate composition of claim 1 which contains 3 to 5 mM glutathione.
Claim 6
Dependent Claim 48 words
A perfusate composition consisting essentially of the following: ______________________________________ Component mMols Gms/liter ______________________________________ Hydroxyethyl starch, 55 gms MW = 500,000 Glucose 10.0 1.8 Sodium bicarbonate 10.0 0.84 Potassium chloride 28.34 2.11 Calcium chloride 1.0 0.11 Magnesium chloride 1.0 0.095 HEPES or THAM 7.2 1.72 Mannitol 170 30.97 ______________________________________
Claim 7
Dependent Claim 48 words
A perfusate composition consisting essentially of the following: ______________________________________ Component mMols Gms/liter ______________________________________ Hydroxyethyl starch, 55 gms MW = 500,000 Glucose 10.0 1.8 Sodium bicarbonate 10.0 0.84 Potassium chloride 28.34 2.11 Calcium chloride 1.0 0.11 Magnesium chloride 1.0 0.095 HEPES or THAM 7.2 1.72 Mannitol 170 30.97 ______________________________________

References Cited (Backward Citations)

US3523938A Cited
DE3030863A1 Cited
US4798824A Cited
US4873230A Cited
US4879283A Cited
US4923442A Cited
US4920044A Cited

USPTO Annuity & Maintenance Windows

Annuity Stage Window Opens Payment Deadline Surcharge Period Until Estimated Fee Status
3.5 Years (Year 4) 1995-01-20 1995-07-22 1996-01-21 $2000.00 Window Closed / Lapsed
7.5 Years (Year 8) 1999-01-20 1999-07-22 2000-01-21 $3760.00 Window Closed / Lapsed
11.5 Years (Year 12) 2003-01-20 2003-07-22 2004-01-21 $7700.00 Window Closed / Lapsed

Assigned Categories & Tags

No categories assigned to this patent yet.

Assign Category Tag